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Abstract
Histone deacetylase (HDAC) inhibitors have been shown to induce cell cycle arrest and apoptosis in cancer cells. How-
ever, the mechanisms of HDAC inhibitor induced apoptosis are incompletely understood. In this study, depsipeptide, a
novel HDAC inhibitor, was shown to be able to induce significant apoptotic cell death in human lung cancer cells.
Further study showed that Bim, a BH3-only proapoptotic protein, was significantly upregulated by depsipeptide in can-
cer cells, and Bim’s function in depsipeptide-induced apoptosis was confirmed by knockdown of Bim with RNAi. In
addition, we found that depsipeptide-induced expression of Bim was directly dependent on acetylation of forkhead box
class O1 (FoxO1) that is catalyzed by cyclic adenosine monophosphate–responsive element-binding protein–binding
protein, and indirectly induced by a decreased four-and-a-half LIM-domain protein 2. Moreover, our results demon-
strated that FoxO1 acetylation is required for the depsipeptide-induced activation of Bim and apoptosis, using transfec-
tion with a plasmid containing FoxO1 mutated at lysine sites and a luciferase reporter assay. These data show for the
first time that an HDAC inhibitor induces apoptosis through the FoxO1 acetylation-Bim pathway.
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Introduction
Bim is a proapoptotic BH3 domain-only member of the Bcl-2 family,
which is required for hematopoietic cell homeostasis and acts as a bar-
rier against autoimmune disease [1]. Recently, it has been reported that
Bim is involved in the regulation of apoptosis in many different types
of cells [2–7]. The apoptotic activity of Bim was thought to be medi-
ated through several possible mechanisms including activation of Bax
or Bak [3,4,8]. Bim’s expression is also tightly regulated by Rb-E2F1
[9], phosphatidylinositol 3-kinase (PI3-K)/protein kinase B (PKB)
[10], or the extracellular signal–regulated kinase/mitogen-activated
protein kinase pathway [11,12].
The forkhead box transcription factor, class O (FoxO), is a mam-
malian homolog of DAF-16, which is known to regulate life span in
Caenorhabditis elegans [13,14]. The FoxO factors including FoxO1,
FoxO3a, FoxO4, and FoxO6 share DNA-binding specificity to a core
consensus site called the forkhead-responsive element [15–19] and
regulate the transcription of genes involved in several cellular processes
such as cell cycle arrest, apoptosis, and DNA repair in response to
oxidative stress, differentiation, or glucose metabolism [10,18,20,21].
Among the FoxO members, FoxO1 activity is negatively regulated by
PI3-K/Akt, which phosphorylates FoxO1 at multiple sites and forces
FoxO1 into the cytoplasm, and thus, decreases its transcriptional activ-
ity [18,21–23]. Recently, cell death induced by FoxO3a was reported to
be mediated through Bim, which is one of the FoxO-target genes [23–
25]. It was thus important to clarify whether FoxO1 is also involved in
the process of Bim-induced apoptosis.
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Posttranslational modification of FoxOs, and especially phosphoryla-
tion, is considered to play an important role in activating Bim [25,26].
For example, saturated free fatty acids were reported to induce de-
phosphorylation of FoxO3a and in turn induce the expression of the
intracellular death mediator Bim [25]. In addition, atorvastatin, an anti-
oxidant reagent, prevents H2O2-induced apoptosis by increasing phos-
phorylation of FoxO4 and thus reducing the expression of Bim in
endothelial progenitor cells [26]. Other posttranslational modifications
such as acetylation have also been identified. The acetylation status of
FoxOs is regulated by a balance between proteins with histone acetylase
activity and proteins with histone deacetylase (HDAC) activity. Cy-
clic adenosine monophosphate–responsive element-binding protein–
binding protein (CBP) and p300 have been found to be able to induce
acetylation of FoxO proteins [14,18,27]. In addition to acetylases, pro-
teins with HDAC activity such as sirtuin 1 (SIRT1) or a four-and-a-half
LIM-domain protein 2 (FHL2) have been reported to be involved in
the acetylation of FoxOs and the expression of Bim [27–29]. Thus, it is
of value to clarify whether acetylation of FoxO1 is involved in HDAC
inhibitors–induced apoptosis.
Histone deacetylase inhibitors have been extensively studied and
have been used as potential therapeutic agents for tumors including
leukemia [30–35]. Histone deacetylase inhibitors are also reported to
induce acetylation of nonhistone proteins [36,37] and to have the
ability to acetylate hyperacetylated nucleosome core histones [30]
or to demethylate DNA [38]. The importance of HDAC inhibitors
in clinical therapy is based on the ability of almost all HDAC inhibi-
tors to induce a range of antitumor activities including induction of
apoptosis [30,39–41]. Several HDAC inhibitors were reported to in-
duce apoptosis in tumor cells by increasing the expression of Bim
or other related genes [9,42–47]. For example, Bim was reported
to play an important role in the apoptotic and therapeutic activities
of HDAC inhibitors on the basis of a mouse model of B-cell lym-
phoma [46]. Histone deacetylase inhibitors were also found to induce
apoptosis of tumor cells from patients with chronic lymphocytic leu-
kemia through Bim and Noxa [47]. However, although HDAC inhibi-
tors show activity in the induction of Bim-associated apoptosis, the exact
mechanisms underlying this effect are not well understood.
In this study, human lung cancer cell lines H460, H719, A549,
and H1299 were treated with the HDAC inhibitor depsipeptide to
explore the mechanism of depsipeptide-induced apoptosis. We found
that Bim plays a pivotal role in depsipeptide-induced apoptosis in
some of these cells. Furthermore, FoxO1 acetylation was confirmed
to be required for the activation of Bim, which is catalyzed by CBP,
and a weakened association of SIRT1 and FoxO1 in response to depsi-
peptide treatment.
Materials and Methods
Cell Lines and Cell Culture
Human lung cancer cell lines A549, H1299, NCI-H460, and H719
were grown in RPMI 1640 supplemented with 10% fetal bovine serum
(heat inactivated at 56°C for 45 minutes) and an appropriate amount
of penicillin/streptomycin in a 37°C incubator with a humidified 5%
CO2 atmosphere.
Reagents
The HDAC inhibitor depsipeptide was kindly provided by the
National Institutes of Health and was dissolved in DMSO to a stock
concentration of 50 μM and stored at 4°C. The HDAC inhibitors
suberoylanilide hydroxamic acid (SAHA) and apicidin were purchased
from Sigma (St. Louis, MO).
Flow Cytometry Assay
The DNA content of cultured cells was analyzed by flow cytometry
assay as previously described [48]. Apoptotic cells have a lower DNA
content than that in normal cells and appear as a pre-G1 peak on a
DNA cell cycle histogram, and cells were harvested to quantitate the
amount of apoptosis present after various treatments. In brief, cells
were trypsinized and washed once with cold phosphate-buffered saline.
Cells were then fixed with 70% ethanol and stored overnight at
−20°C. Propidium iodide (10 μg/ml; Sigma) was added to stain cells
in the presence of RNase (Promega, Madison, WI) at 37°C for 10 min-
utes, and cells were then analyzed on a FACscan Flow Cytometer with
manual gating using CellQuest software.
Colony Formation Assay
A549 and H1299 cells were treated with different doses of depsi-
peptide, and appropriate cell numbers were plated in triplicate into
six-well plates for survival determination. Cells were incubated for 10
to 14 days at 37°C incubator to allow for colony formation. Colonies
(a colony was defined as containing >50 cells) were then fixed with
methanol/acetic acid and stained with crystal violet.
Reverse Transcription–Polymerase Chain Reaction
Primers for polymerase chain reaction (PCR) were designed as
follows: Bim-F, 5′-GAGAAGGTAGACAATTGCAG-3′, Bim-R,
5′-GACAATGTAACGTAACAGTCG-3′; FoxO1-F, 5′-CTCCCA-
TACCCACCCTG-3′, FoxO1-R, 5′-AATGAACATGCCATCCA-
AG-3′; FHL2-F, 5′-GCCAAGAAGTGTGCTGGG-3′, FHL2-R,
5′-GCAACGGGAGGTTACAGAG-3′; SIRT1-F, 5′-CCTGACTT-
CAGATCAAGAGACGGTA-3′, SIRT1-R, 5′-CTGATTAAAAA-
TGTCTCCACGAACAG-3′; p27-F, 5′-TGGAGAAGCACTGCA-
GAGAC-3′, p27-R, 5′-GCGTGTCCTCAGAGTTAGCC-3′;
GADD45-F, 5 ′ -CCATGCAGGAAGGAAAACTATG-3 ′ ,
GADD45-R, 5′-CCCAAACTATGGCTGCACACT-3′; CBP-F, 5′-
GGGCCTGTCATCAACACCC-3′, CBP-R, 5′-CGTAGTCCTC-
GCACACAGTG-3′. The PCR products were run on 2% agarose gels,
stained with ethidium bromide, and evaluated with UV light.
Plasmids and Small Interfering RNA Transfection
Plasmids used for transfection in this study included the mutant
FoxO1 with acetylation sites 3KR in which lysine (Lys-242, Lys-245,
and Lys-262) was replaced by arginine (gifts from Akiyoshi Fukamizu)
and wild-type FoxO1 (purchased from Addgene). The Bim small
interfering RNA (siRNA) sequence was designed as 5′-CAAUUGU-
CUACCUUCUCGG-3′, and the nonspecific siRNA (control) se-
quence was designed as 5′-GACCACGAGUAAAAGUAGU-3′ [49].
The FoxO1 siRNA sequence was designed as 5′-GAGCGTGCCC-
TACTTCAAG-3′, and the nonspecific siRNA (control) sequence was
designed as 5′-CCACTACCTGAGCACCCAG-3′ [50]. The FoxO3a
siRNA sequence was designed as 5′-GAGCUCUUGGUGGAUCA-
UCTT-3′ [51]. The FHL2 siRNA sequence was designed as 5′-UCU-
CUCUUUGGCAAGAAGU-3′ [52]. The CBP siRNA sequence was
designed as 5′-TAGTAACTCTGGCCATAGC-3′ [53]. These RNAi
oligonucleotides were purchased from Genechem (Shanghai, China).
After transfection, the cells were harvested and subjected toWestern blot
analysis, reverse transcription–PCR (RT-PCR), or Luciferase assay.
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Luciferase Assay
H1299 cells were plated on 24-well plates after treatment and
were incubated until 60% to 80% confluency was reached. Cells
were transfected with a Bim-pGL3 luciferase reporter construct (kindly
provided by Qiang Yu) [9] using the GenePORTER transfection
reagent (Gene Therapy Systems, Inc., San Diego, CA). After trans-
fection, cells were incubated in the presence or absence of depsi-
peptide for 12 hours. Luciferase activity in cell lysates was measured
with the Luciferase assay system (Promega) and normalized for protein
in the cell lysate. The results are the relative luciferase activity of the
treated cells over that of the control cells. All transfection experiments
were carried out in triplicate wells and were repeated separately at least
three times.
Western Blot Analysis
Protein expression was detected by Western blot analysis as previ-
ously described with minor modifications [54]. Equal amounts of
proteins (100 to 150 μg) were size fractionated by 9 to 15% sodium
dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis. Anti-Bim
(H-191; Santa Cruz Biotechnology, Santa Cruz, CA), anti-Bax (sc-6236;
Santa Cruz Biotechnology), anti-FoxO1 (Cell Signaling Technology,
Beverly, MA), anti-FoxO3a (Cell Signaling), anti-FHL2 (Santa Cruz
Biotechnology), anti-SIRT1 (Santa Cruz Biotechnology), p300 (H-
272; Santa Cruz Biotechnology), CBP (A-22; Santa Cruz Biotech-
nology), P300/CREB binding protein (CBP)–associated factor (PCAF)
(C-16; Santa Cruz Biotechnology), anti–β-actin (Santa Cruz Biotech-
nology), and anti–acetyl-lysine (Upstate Biotechnology, Lake Placid,
NY) were used, and the blots were developed using an enhanced chemi-
luminescence kit (Amersham Corp., Arlington Heights, IL).
Chromatin Immunoprecipitation Assay
H1299 cells were cross-linked with 1% formaldehyde for 10 min-
utes at 37°C and then washed with cold phosphate-buffered saline.
The cell pellet was resuspended in lysis buffer, followed by sonication
to an average DNA length of 500 to 1000 bp. Antibodies were added
to each of the samples, which were then rotated at 4°C overnight.
After interaction with protein A beads and incubation overnight at
65°C to reverse the cross-links, the DNA was dissolved in Tris-EDTA
buffer and analyzed by PCR. The anti-FoxO1 antibodies were added
separately into the reaction solutions. Primers used for PCR were as fol-
lows: Bim: 5′-AGCAAGCAGAGTTACTCCGGTAAACA-3′ (sense)
and 5′-CCCGCTCCTACGCCCAATCA-3′ (antisense); p27: 5′-GT-
CCCTTCCAGCTGTCACAT-3′ (sense) and 5′-GGAAACCAACCT-
TCCGTTCT-3′ (antisense).
Coimmunoprecipitation
A549 cells were harvested and then lysed in lysis buffer (1% NP-40,
150 mM NaCl, 50 mM Tris, 0.05% SDS, 1 mM PMSF, and a 1%
cocktail of protease inhibitors) on ice for 20 minutes. After centri-
fugation at 4°C at 13,000 rpm for 10 minutes, antibodies were added
to the supernatant on ice for 1 hour. Agarose G was then added,
and the samples were rolled at 4°C for 1 hour. After the beads were
washed three times with lysis buffer, the pellets were dissolved into
2× SDS loading buffer after centrifugation. The protein was analyzed
by Western blot analysis with different antibodies.
Data Analysis
Statistical analysis was performed to assess the difference between
the two groups under multiple conditions by one-way analysis of vari-
ance using PRISM statistical analysis software (GraphPad Software,
Inc., San Diego, CA).
Results
Depsipeptide Induces Apoptosis in Human Lung Cancer Cells
In this study, human lung cancer cell lines H460, A549, H719,
and H1299 cells were exposed to depsipeptide, and depsipeptide-
induced cytotoxicity was then evaluated. First, flow cytometry was
performed to analyze changes in cell cycle and cell death in these cells
in response to depsipeptide treatment. The cells with DNA content
smaller than G0/G1 (designated pre-G1 peak on the DNA histogram)
were considered to be apoptotic cells. Although depsipeptide induced
a G2 arrest in all cell lines tested (data not shown), depsipeptide-
induced apoptotic cell death was cell line–dependent. For example,
depsipeptide showed a dose-dependent cytotoxicity to H460, A549,
and H719 cells (Figure 1A). Conversely, depsipeptide was not able to
induce apoptosis in H1299 cells (Figure 1A). Moreover, the change in
poly(ADP-ribose) polymerase (PARP) cleavage (from 116 kDa cleaved
to 89 kDa), which is thought to be a late event in apoptosis, was
observed in depsipeptide-treated A549 cells assayed with Western blot
analysis. As shown in Figure 1B, a dose-dependent increase in cleaved
89-kDa PARP fragments was observed when A549 cells were treated
with depsipeptide, but no cleaved PARP fragments were found in
H1299 cells. To further confirm the effect of depsipeptide induced cell
killing, a colony formation assay was performed. A549 and H1299
cells were treated with depsipeptide at different doses and plated into
six-well plates for colony formation. Figure 1C shows that depsipeptide
induced a significant decrease in colony formation in A549 cells com-
pared with that in H1299 cells. These data showed that depsipeptide-
induced apoptosis of human lung cancer cells was cell line–dependent.
In addition, to evaluate whether A549 cells were sensitive to other
HDAC inhibitors, SAHA and apicidin were also used to perform these
experiments. As shown in Figure 1D, although all HDAC inhibitors
tested induced apoptosis in A549 cells, depsipeptide was much more
effective in inducing apoptosis than other HDAC inhibitors (44.9 ±
1.3% cell apoptosis in depsipeptide-treated cells compared with 6.8 ±
0.5% cell apoptosis in SAHA-treated cells or with 11.7 ± 2.1% cell
apoptosis in apicidin-treated cells), indicating that depsipeptide is a
potent inducer of apoptosis in A549 cells.
Activation of Bim Is Responsible for
Depsipeptide-Induced Apoptosis
It has been reported that Bcl-2 family members are involved in vari-
ous reagent-induced apoptosis [55–57]. To explore the effect of Bcl-2
family members on depsipeptide-induced apoptosis, the expression of
Bcl-2 family proteins including Bcl-2, Bax, and Bim was evaluated by
Western blot analysis. There are three major isoforms of Bim created
by alternative splicing, namely, BimEL, BimL, and BimS, and only
BimEL was readily identifiable by Western blot analysis in our study.
As shown in Figure 2A, expression of BimEL (hereafter referred to as
Bim) was significantly increased in a dose-dependent manner. For ex-
ample, the expression of Bim was increased by 7.0- or 21.0-fold in
A549 cells treated with depsipeptide at 0.05 or 0.1 μM for 24 hours
(Figure 2A). However, the expression of Bcl-2 and Bax was not ob-
viously changed in these cells under identical treatment conditions
(Figure 2A). Next, RT-PCR was performed to investigate whether ac-
tivation of Bim results from transcriptional regulation in A549 cells in-
duced by depsipeptide treatment. As shown in Figure 2B, Bim mRNA
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was obviously increased after depsipeptide treatment. For instance,
depsipeptide (0.05 or 0.1 μM for 24 hours) induced a three- or nine-
fold increase in Bim mRNA. These results suggested that depsipeptide
induced expression of Bim at both protein and mRNA levels. However,
the expression of neither Bim protein nor mRNAwas affected by depsi-
peptide treatment in H1299 cells (Figure 2, C and D). These findings
were consistent with the apoptotic results described above (Figure 1,
A–C) and suggested that Bim may play a major role in inducing apop-
tosis in A549 cells in response to depsipeptide treatment.
To further confirm this observation, A549 cells were transiently
transfected with siRNA against Bim or a nonspecific siRNA (named
as control RNAi) and then treated with depsipeptide. Twenty-four
hours after treatment, cells were harvested and subjected to RT-PCR
or flow cytometry assay. As shown in Figure 2E , depsipeptide (0.05 μM
for 24 hours) induced a six-fold increase in Bim mRNA compared
with that in control RNAi–transfected cells, and the expression of
Bim induced by depsipeptide was effectively reduced after Bim RNAi
transfection. Similarly, the numbers of apoptotic cells after depsipeptide
treatment in A549 cells decreased after transfection with Bim siRNA
as assayed with flow cytometry (Figure 2F ). These data suggest that
depsipeptide-induced apoptosis in A549 cells was modulated by the
proapoptotic protein Bim.
Depsipeptide Induces an Increase in FoxO1 Expression
It is known that Bim is one of the downstream targets of FoxOs
[18,21], and evidence has shown that its expression is mediated by
FoxO3 [20,23,24]. We thus investigated whether depsipeptide-induced
expression of Bim is also mediated through activation of the FoxO
family. However, as shown in Figure 3A, the expression of FoxO3a
was not obviously increased after depsipeptide treatment. To further
exclude FoxO3a activation as the mechanism of depsipeptide-induced
apoptosis, FoxO3a siRNA or a control RNAi was delivered into A549
cells, which were then subjected to depsipeptide treatment. As shown
in Figure 3B, the expression of FoxO3a protein was effectively re-
duced by 90% after transfection with FoxO3a siRNA compared with
that in control RNAi–transfected A549 cells. It was of interest that
depsipeptide-induced apoptosis was not decreased in A549 cells with
FoxO3a knockdown compared with that in control RNAi–transfected
cells as evaluated with flow cytometry (Figure 3B), demonstrating that
depsipeptide-induced apoptosis was FoxO3a-independent. Conversely,
Figure 1. Depsipeptide induces apoptosis in human lung cancer cell lines. (A) Human lung cancer cell lines H460, A549, H719, and
H1299 were treated with or without depsipeptide over a range of 0.01 to 0.1 μM for 24 hours, and cells were then harvested and stained
with propidium iodide (10 μg/ml) to determine their DNA profiles by flow cytometry. Apoptotic cells were evaluated and presented as a
percentage of total cells. *P < .05, **P < .01. (B) A549 and H1299 cells were treated with depsipeptide (0.01 or 0.05 μM) for 24 hours.
Cells were then harvested, and protein was extracted for Western blot analysis to evaluate for PARP cleavage. β-Actin is shown as a
loading control. (C) A549 and H1299 cells were treated with various doses of depsipeptide (0.01 to 0.1 μM) and then plated into six-well
plates for colony formation. After 10 to 14 days, colonies were fixed with methanol/acetic acid, stained with crystal violet, and counted
under a microscope. (D) A549 cells were also treated with or without the HDAC inhibitors SAHA (5 μM) or apicidin (0.5 μM) for com-
parison to depsipeptide treatment (0.05 μM) for 24 hours, and cells were then harvested and stained with propidium iodide (10 μg/ml) to
determine their DNA profiles by flow cytometry. Results are presented as the mean ± SD of three experiments performed in triplicate
for flow cytometry analysis or colony formation. Statistical analysis was carried out with one-way analysis of variance.
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the FoxO1 expression was significantly increased in the depsipeptide-
treated A549 cells (Figure 3C ). This depsipeptide-induced alteration
of FoxO1 expression resulted from transcriptional regulation, in which
depsipeptide was able to induce a significant increase in expression of
FoxO1 mRNA (three-fold increase in depsipeptide-treated cells com-
pared with untreated cells; Figure 3D), showing that depsipeptide-
induced apoptosis was FoxO1-dependent.
In addition, to investigate whether the FoxO1/Bim pathway is
unique to depsipeptide-induced apoptosis, A549 cells were exposed
to the HDAC inhibitors SAHA and apicidin. As shown in Figure 3E ,
there were no obvious changes in mRNA levels of Bim or FoxO1,
suggesting strongly that the FoxO1/Bim pathway is not involved
in SAHA- or apicidin-induced apoptosis in A549 cells.
FoxO1 Mediates Bim Expression in Response to
Depsipeptide Treatment
In view of the fact depsipeptide induced an increase in expression of
both FoxO1 and Bim, we were led to consider whether there is a causal
relation between the increase of FoxO1 and the expression of Bim in
response to depsipeptide treatment. We thus tested whether FoxO1
expression is required for subsequent Bim expression in depsipeptide-
treated cells. A plasmid with wild-type FoxO1 tagged with a green
fluorescent protein (GFP) was transiently transfected into H1299
cells and then treated with depsipeptide (endogenous FoxO1 showed
only very low expression in H1299 cells). As shown in Figure 4A,
depsipeptide induced a significant expression of FoxO1 (three-fold
increase compared with that in cells not treated with depsipeptide
after transfection with GFP-FoxO1). Accompanying this expres-
sion of FoxO1, the expression of Bim was also significantly increased
in response to depsipeptide treatment (Figure 4A). Consequently,
depsipeptide-induced apoptosis was observed only in cells transfected
with the GFP-FoxO1 as assayed with flow cytometry (Figure 4B).
To further clarify these results, A549 cells were transiently transfected
with FoxO1 siRNA or control RNAi and were then treated with depsi-
peptide. As shown in Figure 4C , the expression of FoxO1 was reduced
by 70% after FoxO1 siRNA transfection. Similarly, Bim expression was
also significantly reduced in the FoxO1 siRNA–treated cells compared
with that in control RNAi–treated cells in response to depsipeptide
Figure 2. Activation of Bim is responsible for depsipeptide induced apoptosis. A549 (A) or H1299 cells (C) were treated with depsipeptide
(0.01 to 0.1 μM for 24 hours). Cells were then harvested for Western blot analysis. Specific antibodies were used to evaluate the expression
of Bim, Bcl-2, or Bax. β-Actin is shown as a loading control. A549 (B) or H1299 cells (D) were treated with depsipeptide (0.05 or 0.1 μM for
24 hours), and RNA was then extracted for RT-PCR assay to identify changes in Bim mRNA. GAPDH was used as a loading control for
RT-PCR. (E) A549 cells were transiently transfected with oligonucleotides of Bim siRNA or a control RNAi and then treated with depsi-
peptide (0.05 μM for 24 hours). The cells were then harvested and subjected to RT-PCR to detect Bim expression. GAPDH was used as a
loading control for RT-PCR. (F) After transient transfection with oligonucleotides of Bim siRNA or a control RNAi and treatment with or
without depsipeptide (0.05 μM for 24 hours), A549 cells were harvested and stained with propidium iodide (10 μg/ml) to determine their
DNAprofiles by flowcytometry. For allWesternblot analysis,β-actin is shownasa loading control. Protein andmRNAbandswerescannedby
phosphorimaging, and the relative band intensities were normalized to each β-actin or GAPDH band. The band intensity of untreated sample
was set as 1. The numerical value of each sample represents the percentage of band intensity relative to that of the untreated sample.
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treatment. These findings were consistent with resultant apoptosis as
determined by flow cytometry (Figure 4D). Also, vector-driven FoxO1
siRNA was used to constitutively knockdown the target gene, and a
colony formation assay was performed to confirm the effect of FoxO1
on the expression of Bim and apoptosis induced by depsipeptide. As
shown in Figure 4E , a stable transfection of a FoxO1 RNAi plasmid also
significantly decreased the mRNA level of FoxO1 and Bim in A549
cells, and this decrease in FoxO1 and Bim expression was consistent
with the decrease in apoptosis noted in response to depsipeptide treat-
ment (data not shown). The rate of colony formation in A549 cells with
knockdown of FoxO1 was increased approximately 2.5-fold compared
with that in control RNAi cells (Figure 4F ). Depsipeptide induced
a significant decrease in colony formation rate in control RNAi A549
cells compared with that in the FoxO1 knockdown cells (Figure 4F ).
These results clearly indicate that FoxO1 expression is prerequisite for
the induction of Bim and apoptosis induced by depsipeptide.
FoxO1 Acetylation Is Induced by an Enhanced Recruitment
of CBP to FoxO1 and Is Required for Depsipeptide-Induced
Bim Expression
Because the role of phosphorylation in the regulation of FoxOs’ ac-
tivity has been extensively characterized [18,21], we next tested whether
depsipeptide induces changes in the phosphorylation of FoxO1 at
several key sites including Ser-256. However, no increase in phos-
phorylation of FoxO1 was found at these sites after depsipeptide treat-
ment (data not shown). Thereafter, acetylation changes in FoxO1 after
Figure 3. Depsipeptide induces an increase in FoxO1 expression. (A) A549 cells were treated with depsipeptide (0.05 or 0.1 μM for
24 hours). The cells were then harvested and subjected to Western blot analysis to evaluate FoxO3a expression. (B) A549 cells were
transfected with either oligonucleotides of FoxO3a siRNA or control RNAi and were then treated with depsipeptide (0.05 μM for
24 hours). Cells were harvested and stained with propidium iodide (10 μg/ml) to determine their DNA profiles through flow cytometry
or through Western blot analysis to detect FoxO3a expression. Apoptotic cells were calculated and presented as a percentage of total
cells. (C) A549 cells were treated with depsipeptide (0.05 or 0.1 μM for 24 hours). Cells were then harvested and subjected to Western
blot analysis to evaluate FoxO1 expression. (D) A549 cells were treated with depsipeptide at 0.05 μM for 24 hours, and then mRNA was
extracted, and RT-PCR was performed to identify changes in FoxO1 mRNA. GAPDH was used as a loading control for RT-PCR. (E) A549
cells were treated with SAHA (5 μM) or apicidin (0.5 μM) for 24 hours, and mRNA was then extracted for RT-PCR assay to identify changes
in Bim or FoxO1 mRNA. GAPDH was used as a loading control for RT-PCR. Results are presented as the mean ± SD of three experiments
performed in triplicate for flow cytometry analysis. For each Western blot analysis assay, β-actin is shown as a loading control. Protein and
mRNA bands were scanned by phosphorimaging, and the relative band intensities are shown as mentioned above.
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depsipeptide treatment were investigated using a coimmunoprecipita-
tion (CoIP) assay. An anti–acetyl-lysine antibody was used for detect-
ing total lysine acetylation of all proteins in depsipeptide-treated A549
cells and was followed by probing with anti-FoxO1 antibody. As
shown in Figure 5A, a significant increase in FoxO1 acetylation was
confirmed in these depsipeptide-treated cells (to evaluate acetylation
changes in FoxO1 with depsipeptide treatment, an equal amount of
FoxO1 was loaded as a control). To further determine the mechanism
of depsipeptide-induced lysine acetylation, a CoIP assay was performed
to test the interaction of coactivators (PCAF, CBP, or p300) with
FoxO1 in the treated cells. As shown in Figure 5B, depsipeptide in-
duced an enhancement of recruitment of CBP to FoxO1 (six-fold in-
crease in depsipeptide-treated cells compared with that in the untreated
control). However, depsipeptide did not enhance the interaction of
p300 with FoxO1 (Figure 5B). In addition, no interaction of PCAF
with FoxO1 was found in A549 cells (data not shown).
We next investigated the role of CBP-catalyzed acetylation of
FoxO1 in activating Bim. A mutant FoxO1-3KR, in which the CBP-
dependent acetylation residues sites (Lys-242, Lys-245, and Lys-262)
were replaced by arginine, was used for this portion of the study.
H1299 cells were transiently transfected with the mutated plasmid or
nonspecific plasmid and were then treated with depsipeptide. As shown
Figure 4. FoxO1 mediates Bim expression in response to depsipeptide treatment. (A) H1299 cells were treated with depsipeptide
(0.05 μM for 24 hours) after transfection with wide-type FoxO1 or a nonspecific plasmid, and cells were then harvested and subjected
to Western blot analysis to identify FoxO1 or Bim expression. (B) Under the same stimulated condition, cells were harvested and stained
with propidium iodide (10 μg/ml) to determine their DNA profiles by flow cytometry. Apoptotic cells were counted and presented as a
percentage of total cells. *P < .05. (C) A549 cells were transiently transfected with oligonucleotides of FoxO1 siRNA or a control RNAi
and then treated with depsipeptide (0.05 μM for 24 hours). The cells were then harvested and subjected to Western blot analysis to
identify the expression of FoxO1 and Bim. (D) Under the same stimulated condition, cells were harvested and stained with propidium
iodide (10 μg/ml) to determine their DNA profiles by flow cytometry. Apoptotic cells were counted and presented as a percentage of
total cells. (E) A549 cells were transfected with a FoxO1 RNAi plasmid. Cells with knockdown of FoxO1 were treated with depsipeptide
(0.05 μM for 24 hours) and then harvested to perform RT-PCR to detect FoxO1 and Bim expression. (F) A549 cells were treated with
various doses of depsipeptide (0.01 to 0.1 μM) and then plated into six-well plates for colony formation. After 10 to 14 days, colonies
were fixed with methanol/acetic acid, stained with crystal violet, and counted under a microscope. Results are presented as the mean ±
SD of three experiments performed in triplicate for flow cytometry analysis or colony formation. For each Western blot analysis assay,
β-actin is shown as a loading control.
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in Figure 5C , neither did depsipeptide induce any obvious increase in
expression of mutated FoxO1 nor was expression of Bim increased in
response to depsipeptide treatment. To further confirm the operation
of this mechanism, a luciferase assay was performed to analyze trans-
criptional activity of FoxO1 on the Bim promoter. H1299 cells were
transfected with CBP siRNA or control RNAi and were then trans-
fected with a Bim-pGL3 luciferase reporter construct combined with
wild-type GFP-FoxO1 or mutant FoxO1-3KR. After this treatment,
cells were incubated in the presence or absence of depsipeptide at
0.05 μM for 12 hours, and relative luciferase activity was measured.
The relative luciferase activity of Bim was increased 13.3-fold in cells
with wild-type FoxO1 transfected in response to depsipeptide treatment
compared with that in control H1299 cells (Figure 5D). However, rela-
tive luciferase activity was not significantly increased after depsipeptide
treatment in cells transfected with mutant FoxO1-3KR (Figure 5D). It
was of interest that the increase in relative luciferase activity induced by
Figure 5. FoxO1 acetylation is induced by enhanced recruitment of CBP to FoxO1 and is required for depsipeptide induced Bim expres-
sion. (A) A549 cells were treated with depsipeptide (0.05 μM for 12 hours), and protein was extracted for CoIP using anti–acetyl-lysine
antibody, followed by Western immunoblot analysis with anti-FoxO1. Before and after depsipeptide treatment, identical amounts of
FoxO1 were used as a loading control as shown as input. (B) After depsipeptide (0.05 μM) treatment, the protein from A549 cells
was extracted for CoIP with anti-CBP or p300, followed by Western immunoblot analysis with anti-FoxO1. The blots were also reprobed
with CBP or p300 antibody as loading controls. (C) H1299 cells were treated with depsipeptide (0.05 μM for 24 hours) after transfection
with a mutant FoxO1-3KR plasmid or a nonspecific plasmid. The cells were then harvested and subjected to Western blot analysis to
detect FoxO1 or Bim expression. β-Actin is shown as a loading control. (D) H1299 cells were plated on 24-well plates after transfection
with CBP siRNA or control siRNA and then transfected with Bim-pGL3 luciferase reporter construct (containing putative FoxO1-binding
sites) combined with wild-type GFP-FoxO1, mutant FoxO1-3KR, or nonspecific plasmids according to experimental design. After trans-
fection, cells were incubated in the presence or absence of depsipeptide for 12 hours, and luciferase activity was measured. Results are
presented as the mean ± SD of four experiments done in triplicate. (E) H1299 cells were transfected with a wild-type FoxO1 or mutant
FoxO1-3KR plasmid and were then treated with depsipeptide (0.05 μM). After 24 hours, cells were harvested for ChIP assay with a
special sequence of the Bim promoter by using anti-FoxO1. The bands with anti-IgG served as negative controls. (F) H1299 cells were
treated with depsipeptide (0.05 μM for 24 hours) after transfection with wild-type FoxO1 or mutant FoxO1-3KR plasmid, harvested, and
stained by propidium iodide (10 μg/ml) to determine their DNA profiles by flow cytometry. Results are presented as the mean ± SD of
three experiments performed in triplicate for flow cytometry analysis. Protein bands were scanned by phosphorimaging, and the rela-
tive band intensities are shown as mentioned above.
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depsipeptide treatment in the wild-type FoxO1-transfected cells was
significantly reduced when the cells were pretransfected with CBP-
RNAi (5.6-fold increase in relative luciferase activity). These data in-
dicated that depsipeptide induced Bim transcriptional activity through
FoxO1 acetylation.
In addition, a chromatin immunoprecipitation (ChIP) assay was
performed to determine whether acetylated FoxO1 directly binds to
the Bim promoter. Figure 5E showed that binding of FoxO1 to the
Bim promoter was significantly increased when cells were treated
with depsipeptide. However, mutated FoxO1 was not able to bind
to the Bim promoter. These data were consistent with the results of
depsipeptide-induced apoptosis in H1299 cells (Figure 5F ), in which
depsipeptide did not induce apoptosis in the H1299 cells transfected
with FoxO1-3KR, suggesting that FoxO1 acetylation resulting in the
recruitment of CBP is required for the depsipeptide-induced apoptosis.
Depsipeptide Also Acetylates FoxO1 Partly through
FHL2-Dependent Decreased Binding of SIRT1 to FoxO1
In addition to histone acetylase activity, some transcription factors
such as SIRT1 exhibit deacetylase activity, which has been reported to
be involved in regulating the acetylation status of FoxOs [27,28]. It is
of interest that although SIRT1 mRNA was not obviously changed
after depsipeptide treatment in A549 cells (Figure 6A), the interaction
between FoxO1 and SIRT1 was reduced in a dose-dependent manner
after depsipeptide treatment as determined by CoIP (Figure 6B),
suggesting that SIRT1 may participate in a depsipeptide-induced
acetylation of FoxO1 in A549 cells. To further confirm this hypothe-
sis, the SIRT1 inhibitor nicotinamide was used to test the effect of
SIRT1-involved acetylation of FoxO1. The mRNA level of Bim was
significantly increased in A549 cells when cells were treated with nico-
tinamide (5 mM for 24 hours; Figure 6C). Similarly, a three-fold in-
crease in FoxO1 acetylation was also observed in nicotinamide-treated
cells, although there was no change in the mRNA level of FoxO1 in
nicotinamide-treated A549 cells (Figure 6, C and D). These data
showed that SIRT1 is involved in regulating the acetylation status of
FoxO1 and thus, mediates the expression of Bim in A549 cells. Next,
we investigated which factor induces a decrease in the interaction of
FoxO1 and SIRT1 in response to depsipeptide treatment, and several
SIRT1-related proteins were investigated. Among the proteins tested,
FHL2 was significantly decreased in response to depsipeptide treat-
ment in A549 cells (Figure 6E), and this led us to consider whether
there might be a link between decreased FHL2 and acetylation of
FoxO1. Using RNAi against FHL2 in A549 cells, we observed that
the interaction of SIRT1 with FoxO1 was significantly decreased
in association with an increase in FoxO1 acetylation in these cells,
although the total amount of SIRT1 remained unchanged (Figure 6,
F–G ). These data were consistent with the results of depsipeptide-
induced apoptosis in FHL2 RNAi A549 cells (Figure 6H ), in which
FHL2 siRNA synergized the effect of depsipeptide in inducing apop-
tosis in the A549 cells. Therefore, FoxO1 acetylation may be also
mediated through an FHL2-dependent decrease in binding of SIRT1
to FoxO1 in response to depsipeptide treatment.
Discussion
Depsipeptide has been reported to induce apoptosis in different
types of cancer cells by multiple pathways including activation of
Bim [45]. However, the exact mechanisms underlying this effect are
not well understood. Our results here demonstrate an additional novel
mechanism by which the HDAC inhibitor depsipeptide induces apop-
tosis in cancer cells through a FoxO1 acetylation-Bim pathway.
In fact, attention has begun to be paid to induction of apoptosis
by pathways involving interaction of FoxO family proteins and Bim.
For example, the FoxO3-Bim pathway has been reported to play a role
in inducing apoptosis in several tumor cell lines in response to various
stimuli [24,58,59]. In addition, FoxO4 was also reported to activate
the Bim promoter and thus induce a FoxO4-dependent apoptosis
[26]. In this study, our data clearly show that FoxO1 is involved in
Bim-regulated apoptosis in response to depsipeptide treatment (Fig-
ure 4). The FoxO1/Bim pathway induced by depsipeptide seems to
be unique because other HDAC inhibitors such as SAHA and apicidin
did not induce obvious changes in FoxO1 or Bim, although apop-
tosis was also partly induced in A549 cells in response to SAHA or
apicidin (Figures 1D and 3E). SAHA can effectively induce cell cycle
arrest (data not shown) instead of apoptosis in A549 cells (Figure 1D),
although SAHA was reported to upregulate the expression of Bim in
human multiple myeloma cell lines [43]. This distinct role played by
SAHA in activating Bim expression may result from a difference in
the tumor cell lines used. Therefore, our data extend understanding
of the mechanistic link between FoxO1 and Bim in response to depsi-
peptide treatment.
We further explored the novel concept link that FoxO1 acetylation is
required for activation of Bim. Posttranslational modification of FoxOs
is a well-identified mechanism for regulating gene expression, which
includes phosphorylation, ubiquitination, and acetylation [14,18,60].
Among the recognized regulators of FoxO phosphorylation, the primary
regulation signal for FoxOs was the PI3-K/Akt signaling pathway
[18,21,60]. FoxO1 was reported to be phosphorylated at three sites
(Thr-24, Ser-256, and Ser-319) in a PI3-K–dependent manner, and
the phosphorylation of all these sites or a subset thereof contributes
to the inactivation of its transcriptional activity [18,21,23,60]. In our
data, phosphorylation of FoxO1 was found not to be important in
the depsipeptide-induced apoptosis in A549 cells (data not shown).
This phosphorylation independent FoxO1 activation may result from
the depsipeptide’s ability to induce an increase in the expression of phos-
phatase and tensin homolog deleted on chromosome ten (data not
shown), which antagonizes the PI3-K/AKT–dependent signaling path-
way [61]. In addition, acetylation of the FoxOs was also reported to play
a key role in activating downstream targets of FoxO1 [27,28]. FoxOs
can interact with proteins such as CBP, p300 [62,63], which have his-
tone acetyltransferases activities in response to oxidative stress and thus
induce increased acetylation of FoxOs [27,28]. Conversely, HDACs
such as SIRT1 have been reported to interact with and deacetylase
FoxO proteins [27–29]. For example, SIRT1 was reported to deacety-
late and represses the activity of FoxO3a [27]. In this study, there are
two possible pathways through which FoxO1 acetylation may have
been induced. First, FoxO1 acetylation may have been induced by
the recruitment of CBP to FoxO1 directly (Figure 5B). Our data were
consistent with the finding that FoxO1 was acetylated in HepG2 cells
by the p300/CBP complex when treated with glucocorticoids and in-
sulin [62]. In addition, CBP was reported to interact with and acetylate
FoxO1 in mouse cells in vitro and in vivo [63]. Second, FoxO1 acetyla-
tion might be mediated indirectly by FHL2 in depsipeptide-treated
A549 cells. The obvious decrease in FHL2 mRNA was accompanied
by a reduced interaction between SIRT1 and FoxO1 after depsipeptide
treatment (Figure 6, B and E). Also, FoxO1 acetylation was found to
be increased in FHL2 siRNA–transfected A549 cells (Figure 6G), show-
ing that FHL2 was involved in decreasing FoxO1 acetylation in A549
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cells. Thus, depsipeptide-induced decrease in FHL2 expression may in-
directly lead to the acetylation of FoxO1 through a decreased association
between SIRT1 and FoxO1.
Finally, we explored the effect of acetylation on the activation of
FoxO1. Acetylation of FoxOs has been shown to have an active
role in inducing downstream gene expression, although debate about
acetylation-associated activation continues [28,62–65]. For example,
FoxO1 acetylation was found to increase FoxO1 stability and thus pro-
tected against pancreatic β cell failure through NeuroD and MafA
induction [64]. Acetylation also enhanced FoxO3 transcriptional activa-
tion and increased the expression of Bim [28]. Conversely, acetylation
of FoxO1 was reported to attenuate its transcriptional activity [63,65].
In this study, we found that acetylation of FoxO1 could increase
Bim’s transcriptional activity in A549 cells in response to depsipeptide
Figure 6. Depsipeptide also acetylates FoxO1 through FHL2-dependent decreased binding of SIRT1 to FoxO1. (A) A549 cells were treated
with depsipeptide (0.05 to 0.1 μM for 24 hours). Cells were then harvested and subjected to RT-PCR to detect the expression of SIRT1.
GAPDH was used as a loading control for RT-PCR. (B) After depsipeptide (0.05 to 0.1 μM) treatment, the protein form A549 cells was ex-
tracted for CoIP with anti-SIRT1, followed by Western immunoblot analysis with anti-FoxO1. The blots were reprobed with SIRT1 antibody
as a loading control. (C) A549 cells were treated with nicotinamide (5 mM for 24 hours). Cells were then harvested and subjected to RT-PCR
to detect the expression of Bim and FoxO1. GAPDH was used as a loading control for RT-PCR. (D) A549 cells were treated with nicotin-
amide (5 mM for 24 hours), and protein was extracted for CoIP using anti–acetyl-lysine antibody, followed by Western immunoblot analy-
sis with anti-FoxO1. Before and after depsipeptide treatment, identical amounts of FoxO1 were used as a loading control (input). (E) A549
cells were treated with depsipeptide (0.05 to 0.1 μM for 24 hours). The cells were then harvested and subjected to RT-PCR to detect the
expression of FHL2. GAPDH was used as a loading control for RT-PCR. (F) A549 cells were transfected with either oligonucleotides of
FHL2 siRNA or a control RNAi, and protein was then extracted for Western blot analysis to detect the expression of FHL2. β-Actin is shown
as a loading control. (G) At the same stimulated condition, cells were harvested for CoIP by using anti–acetyl-lysine and SIRT1 antibody,
followed by Western immunoblot analysis with anti-FoxO1. As a control, identical amounts of FoxO1 were loaded as shown in input.
(H) A549 cells were treated with depsipeptide (0.05 μM for 24 hours) after transfection either with oligonucleotides of FHL2 siRNA or with
a control RNAi, harvested, and stained by propidium iodide (10 μg/ml) to determine their DNA profiles by flow cytometry. Results are
presented as the mean ± SD of three experiments performed in triplicate for flow cytometry analysis. Protein and mRNA bands were
scanned by phosphorimaging, and the relative band intensities are shown as mentioned above.
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treatment. FoxO1 mutated at acetylation sites exhibited a reduced
ability to bind to the Bim promoter and a decreased apoptosis in
response to depsipeptide treatment (Figure 5, E and F ), indicating
that depsipeptide-induced apoptosis mediated by Bim is modulated
through the FoxO1 acetylation. In addition, the expression of other
downstream targets of FoxO1 including G6Pase, MnSOD, GADD45,
and p27 was investigated in this study. Because the endogenous ex-
pression of G6Pase and MnSOD in A549 cells was not detectable (data
not shown), thus the mRNA level of p27 and GADD45 in A549 cells
in response to depsipeptide treatment was determined. In distinction
to GADD45, both p27 mRNA and binding of FoxO1 to the p27 pro-
moter were reduced in A549 cells after depsipeptide treatment (Fig-
ure W1, A and B), which is consistent with previous reports [63].
These results reflect the fact that depsipeptide-induced acetylation of
FoxO1 is a unique modification that activates Bim expression, through
which apoptotic cell death is elicited.
In summary, we identified a novel pathway, FoxO1/Bim, which
activates apoptotic cell death in response to depsipeptide treatment.
Understanding the role of acetylation of FoxO1 on its downstream
activation targets will likely be useful in designing more effective
therapeutic strategies for the treatment of cancer.
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Figure W1. Depsipeptide reduces expression of p27. (A) A549 cells
were treated with depsipeptide (0.05 μM for 24 hours). Cells were
then harvested and subjected to RT-PCR to detect expression
of p27 and GADD45. GAPDH was used as a loading control for
RT-PCR. (B) H1299 cells were transfected with a wild-type FoxO1
or mutant FoxO1-3KR plasmid and then treated with depsipeptide
(0.05 μM). After 12 hours, cells were harvested for ChIP assay with
a special sequence of the p27 promoter by using anti-FoxO1. The
bands with anti-IgG served as negative controls. The numerical
values of ChIP signal represent the percentages of input. mRNA
bands were scanned by phosphorimaging, and the relative band
intensities are shown as mentioned above.
